JPH01500116A - インシユリン製剤 - Google Patents

インシユリン製剤

Info

Publication number: JPH01500116A
Authority: JP; Japan
Prior art keywords: insulin; derivatives; administration; physiological; solution
Prior art date: 1986-04-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP62502696A

Other languages

English (en)

Japanese (ja)

Inventor

バルシユミツト．ペル

ハンセン，フイン　ベネド

ヨハンセン，ベンテ　ロゼ

Original Assignee

ノボ　ノルデイスク　アクツイエセルスカプ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-04-18

Filing date

1987-04-14

Publication date

1989-01-19

1987-04-14 Application filed by ノボ　ノルデイスク　アクツイエセルスカプ filed Critical ノボ　ノルデイスク　アクツイエセルスカプ

1989-01-19 Publication of JPH01500116A publication Critical patent/JPH01500116A/ja

Status Pending legal-status Critical Current

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 171
102000004877 Insulin Human genes 0.000 title claims description 77
108090001061 Insulin Proteins 0.000 title claims description 77
229940125396 insulin Drugs 0.000 title claims description 77
238000002360 preparation method Methods 0.000 title claims description 15
239000000203 mixture Substances 0.000 claims description 27
238000009472 formulation Methods 0.000 claims description 22
238000010521 absorption reaction Methods 0.000 claims description 15
239000000178 monomer Substances 0.000 claims description 6
239000000654 additive Substances 0.000 claims description 4
239000004026 insulin derivative Substances 0.000 claims description 4
238000007911 parenteral administration Methods 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 2
239000003623 enhancer Substances 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims 1
150000003017 phosphorus Chemical class 0.000 claims 1
230000000694 effects Effects 0.000 description 14
239000000243 solution Substances 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
239000000843 powder Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
239000004202 carbamide Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000000034 method Methods 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
238000003756 stirring Methods 0.000 description 5
239000002253 acid Substances 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
-1 polyoxyethylene Polymers 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
101000976075 Homo sapiens Insulin Proteins 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229920005654 Sephadex Polymers 0.000 description 3
239000012507 Sephadex™ Substances 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000000872 buffer Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
210000002850 nasal mucosa Anatomy 0.000 description 3
230000001737 promoting effect Effects 0.000 description 3
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
229930186147 Cephalosporin Natural products 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
108010005991 Pork Regular Insulin Proteins 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
235000012538 ammonium bicarbonate Nutrition 0.000 description 2
239000001099 ammonium carbonate Substances 0.000 description 2
239000003613 bile acid Substances 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
229940124587 cephalosporin Drugs 0.000 description 2
150000001780 cephalosporins Chemical class 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003925 fat Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
235000011008 sodium phosphates Nutrition 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
229940014800 succinic anhydride Drugs 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010035713 Glycodeoxycholic Acid Proteins 0.000 description 1
WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 1
241001446459 Heia Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
241000023320 Luma <angiosperm> Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229940123452 Rapid-acting insulin Drugs 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
108010026951 Short-Acting Insulin Proteins 0.000 description 1
101000993800 Sus scrofa Insulin Proteins 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
238000002725 brachytherapy Methods 0.000 description 1
VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
239000001639 calcium acetate Substances 0.000 description 1
235000011092 calcium acetate Nutrition 0.000 description 1
229960005147 calcium acetate Drugs 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011033 desalting Methods 0.000 description 1
108700028250 desoctapeptide- insulin Proteins 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
150000002190 fatty acyls Chemical group 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
229960004675 fusidic acid Drugs 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 1
241000411851 herbal medicine Species 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229960005232 insulin (human) Drugs 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
229940052404 nasal powder Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NFIYTPYOYDDLGO-UHFFFAOYSA-N phosphoric acid;sodium Chemical compound [Na].OP(O)(O)=O NFIYTPYOYDDLGO-UHFFFAOYSA-N 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
AMCPECLBZPXAPB-UHFFFAOYSA-N propane-1,2,3-triol;sodium Chemical compound [Na].OCC(O)CO AMCPECLBZPXAPB-UHFFFAOYSA-N 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
108700004121 sarkosyl Proteins 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 description 1
IWQPOPSAISBUAH-VOVMJQHHSA-M sodium;2-[[(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyl-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylheptanoyl]amino]ethanesulfonate Chemical compound [Na+].C1C[C@@H](O)[C@@H](C)[C@@H]2CC[C@]3(C)[C@@]4(C)C[C@H](C(C)=O)/C(=C(C(=O)NCCS([O-])(=O)=O)/CCCC(C)C)[C@@H]4C[C@@H](O)[C@H]3[C@]21C IWQPOPSAISBUAH-VOVMJQHHSA-M 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
108700009606 tetrakis(3-nitro-Tyr)- insulin Proteins 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000000052 vinegar Substances 0.000 description 1
235000021419 vinegar Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Toxicology (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Otolaryngology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

JP62502696A 1986-04-18 1987-04-14 インシユリン製剤 Pending JPH01500116A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK1792/86		1986-04-18
DK179286A DK179286D0 (da)	1986-04-18	1986-04-18	Insulinpraeparat

Publications (1)

Publication Number	Publication Date
JPH01500116A true JPH01500116A (ja)	1989-01-19

Family

ID=8108089

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP62502696A Pending JPH01500116A (ja)	1986-04-18	1987-04-14	インシユリン製剤

Country Status (13)

Country	Link
US (1)	US5053389A (da)
EP (1)	EP0267208B1 (da)
JP (1)	JPH01500116A (da)
AT (1)	ATE66614T1 (da)
AU (1)	AU598543B2 (da)
CA (1)	CA1283358C (da)
DE (1)	DE3772521D1 (da)
DK (2)	DK179286D0 (da)
ES (1)	ES2007607A6 (da)
FI (1)	FI87529C (da)
IL (1)	IL82209A0 (da)
NO (1)	NO875299L (da)
WO (1)	WO1987006137A1 (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9387176B2 (en)	2007-04-30	2016-07-12	Novo Nordisk A/S	Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2062227T3 (es) *	1989-08-21	1994-12-16	Hoffmann La Roche	Composiciones farmaceuticas no parenterales para la insulina.
IL99699A (en)	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FR2686899B1 (fr) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP1607086A1 (en) *	1993-01-29	2005-12-21	Aradigm Corporation	Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6131567A (en) *	1993-01-29	2000-10-17	Aradigm Corporation	Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
TW360548B (en) *	1993-04-08	1999-06-11	Powderject Res Ltd	Products for therapeutic use
US6893664B1 (en)	1996-06-17	2005-05-17	Powderject Research Limited	Particle delivery techniques
US5948751A (en) *	1996-06-20	1999-09-07	Novo Nordisk A/S	X14-mannitol
UA65549C2 (uk) *	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AR012894A1 (es)	1997-06-13	2000-11-22	Lilly Co Eli	Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
DK1283051T3 (da) *	1997-06-13	2006-10-16	Lilly Co Eli	Stabile insulinformuleringer
US20010007853A1 (en) *	1998-01-08	2001-07-12	Dimarchi Richard Dennis	Method for administering monomeric insulin analogs
US7070799B1 (en) *	1998-02-10	2006-07-04	Generex Pharmaceuticals, Inc.	Method for administering insulin to the buccal region
US6221378B1 (en)	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
US6350458B1 (en)	1998-02-10	2002-02-26	Generex Pharmaceuticals Incorporated	Mixed micellar drug deliver system and method of preparation
US7087215B2 (en) *	1998-12-21	2006-08-08	Generex Pharmaceuticals Incorporated	Methods of administering and enhancing absorption of pharmaceutical agents
US6375975B1 (en)	1998-12-21	2002-04-23	Generex Pharmaceuticals Incorporated	Pharmaceutical compositions for buccal and pulmonary application
US6451286B1 (en)	1998-12-21	2002-09-17	Generex Pharmaceuticals Incorporated	Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US6849263B2 (en) *	1998-12-21	2005-02-01	Generex Pharmaceutical Incorporated	Pharmaceutical compositions for buccal delivery of pain relief medications
US6294153B1 (en)	1998-12-21	2001-09-25	Generex Pharmaceuticals, Inc.	Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6350432B1 (en)	1999-03-19	2002-02-26	Generex Pharmaceuticals Incorporated	Pressurized container having an aerosolized pharmaceutical composition
US6485706B1 (en)	1999-06-04	2002-11-26	Delrx Pharmaceutical Corp.	Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
GB2355009A (en) *	1999-07-30	2001-04-11	Univ Glasgow	Peptides conjugated to bile acids/salts
EP2213743A1 (en)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albumin fusion proteins
US8061006B2 (en)	2001-07-26	2011-11-22	Powderject Research Limited	Particle cassette, method and kit therefor
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
US8147426B2 (en) *	2003-12-31	2012-04-03	Nipro Diagnostics, Inc.	Integrated diagnostic test system
US20090099064A1 (en) *	2006-06-08	2009-04-16	Diabecore Medical Inc.,	Derivatized insulin oligomers
EP3050568B1 (en)	2007-03-13	2020-12-02	JDS Therapeutics, LLC	Methods and compositions for the sustained release of chromium
WO2009002867A2 (en)	2007-06-26	2008-12-31	Nutrition 21, Inc.	Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
EP2077132A1 (en)	2008-01-02	2009-07-08	Boehringer Ingelheim Pharma GmbH & Co. KG	Dispensing device, storage device and method for dispensing a formulation
EP2414560B1 (de)	2009-03-31	2013-10-23	Boehringer Ingelheim International GmbH	Verfahren zur beschichtung einer oberfläche eines bauteils
JP5763053B2 (ja)	2009-05-18	2015-08-12	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	アダプタ、吸入器具及びアトマイザ
US10016568B2 (en)	2009-11-25	2018-07-10	Boehringer Ingelheim International Gmbh	Nebulizer
BR112012012475B1 (pt)	2009-11-25	2020-03-03	Boehringer Ingelheim International Gmbh	Nebulizador
WO2011064163A1 (en)	2009-11-25	2011-06-03	Boehringer Ingelheim International Gmbh	Nebulizer
WO2011160932A1 (en)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Nebulizer
EP4070801A1 (en)	2011-03-01	2022-10-12	Nutrition 21, LLC	Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
EP2694220B1 (de)	2011-04-01	2020-05-06	Boehringer Ingelheim International GmbH	Medizinisches gerät mit behälter
US9827384B2 (en)	2011-05-23	2017-11-28	Boehringer Ingelheim International Gmbh	Nebulizer
WO2013152894A1 (de)	2012-04-13	2013-10-17	Boehringer Ingelheim International Gmbh	Zerstäuber mit kodiermitteln
ES2836977T3 (es)	2013-08-09	2021-06-28	Boehringer Ingelheim Int	Nebulizador
JP6643231B2 (ja)	2013-08-09	2020-02-12	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ネブライザ
CN116036425A (zh)	2014-05-07	2023-05-02	勃林格殷格翰国际有限公司	喷雾器、指示器装置及容器
IL247927B (en)	2014-05-07	2022-09-01	Boehringer Ingelheim Int	Container, a device that turns a liquid into a fine spray and use
WO2015169430A1 (en)	2014-05-07	2015-11-12	Boehringer Ingelheim International Gmbh	Nebulizer
CA3014308A1 (en)	2016-02-11	2017-08-17	Nutrition 21, Llc	Chromium containing compositions for improving health and fitness

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58189118A (ja) *	1982-04-30	1983-11-04	Takeda Chem Ind Ltd	経鼻投与製剤
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
JPS60224616A (ja) *	1984-04-24	1985-11-09	Teijin Ltd	経鼻投与用組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1381273A (en) *	1971-01-28	1975-01-22	Nat Res Dev	Insulin derivatives
IE36225B1 (en) *	1971-01-28	1976-09-15	Nat Res Dev	Improvements relating to insulin derivatives
GB1381274A (en) *	1971-01-28	1975-01-22	Nat Res Dev	Insulin derivatives
DK135268A (da) *	1973-02-09
US4153689A (en) *	1975-06-13	1979-05-08	Takeda Chemical Industries, Ltd.	Stable insulin preparation for nasal administration
US4164573A (en) *	1975-06-13	1979-08-14	Galinsky Alvin M	Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal
GB1554157A (en) *	1975-06-13	1979-10-17	Takeda Chemical Industries Ltd	Stable insulin preparation for intra nasal administration
GB1527605A (en) *	1975-08-20	1978-10-04	Takeda Chemical Industries Ltd	Insulin preparation for intranasal administration
US4442090A (en) *	1980-11-09	1984-04-10	Kyoto Yakuhin Kogyo Kabushiki Kaisha	Absorption-promoting compounds, compositions thereof with pharmaceuticals and/or bases for rectal administration and method of use
DE3382112D1 (de) *	1982-04-30	1991-02-21	Ajinomoto Kk	Pharmazeutische zusammensetzung.
US4534894A (en) *	1982-11-17	1985-08-13	The Rockefeller University	Process for sulphation and phosphorylation of proteins and peptides
IL68769A (en) *	1983-05-23	1986-02-28	Hadassah Med Org	Pharmaceutical compositions containing insulin for oral administration
US4746508A (en) *	1983-06-06	1988-05-24	Beth Israel Hospital Assn.	Drug administration

1986
- 1986-04-18 DK DK179286A patent/DK179286D0/da not_active Application Discontinuation
1987
- 1987-04-10 CA CA000534467A patent/CA1283358C/en not_active Expired - Lifetime
- 1987-04-13 IL IL82209A patent/IL82209A0/xx not_active IP Right Cessation
- 1987-04-14 WO PCT/DK1987/000038 patent/WO1987006137A1/en not_active Ceased
- 1987-04-14 EP EP87902450A patent/EP0267208B1/en not_active Expired - Lifetime
- 1987-04-14 JP JP62502696A patent/JPH01500116A/ja active Pending
- 1987-04-14 AT AT87902450T patent/ATE66614T1/de active
- 1987-04-14 AU AU73561/87A patent/AU598543B2/en not_active Ceased
- 1987-04-14 DE DE8787902450T patent/DE3772521D1/de not_active Expired - Lifetime
- 1987-04-14 US US07/132,969 patent/US5053389A/en not_active Expired - Fee Related
- 1987-04-15 ES ES8701124A patent/ES2007607A6/es not_active Expired
- 1987-12-08 DK DK642587A patent/DK160460C/da not_active IP Right Cessation
- 1987-12-16 FI FI875533A patent/FI87529C/fi not_active IP Right Cessation
- 1987-12-17 NO NO875299A patent/NO875299L/no unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58189118A (ja) *	1982-04-30	1983-11-04	Takeda Chem Ind Ltd	経鼻投与製剤
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
JPS60224616A (ja) *	1984-04-24	1985-11-09	Teijin Ltd	経鼻投与用組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9387176B2 (en)	2007-04-30	2016-07-12	Novo Nordisk A/S	Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein

Also Published As

Publication number	Publication date
ATE66614T1 (de)	1991-09-15
IL82209A0 (en)	1987-10-30
DK642587D0 (da)	1987-12-08
WO1987006137A1 (en)	1987-10-22
DK642587A (da)	1987-12-08
EP0267208B1 (en)	1991-08-28
FI875533L (fi)	1987-12-16
US5053389A (en)	1991-10-01
AU7356187A (en)	1987-11-09
DK160460C (da)	1991-08-26
NO875299D0 (no)	1987-12-17
FI87529C (fi)	1993-01-25
DK160460B (da)	1991-03-18
AU598543B2 (en)	1990-06-28
EP0267208A1 (en)	1988-05-18
NO875299L (no)	1987-12-17
CA1283358C (en)	1991-04-23
FI87529B (fi)	1992-10-15
FI875533A0 (fi)	1987-12-16
DE3772521D1 (de)	1991-10-02
DK179286D0 (da)	1986-04-18
ES2007607A6 (es)	1989-07-01

Publication	Publication Date	Title
JPH01500116A (ja)	1989-01-19	インシユリン製剤
US6310038B1 (en)	2001-10-30	Pulmonary insulin crystals
US4654327A (en)	1987-03-31	Quaternary ammonium complexes of heparin
JP5269767B2 (ja)	2013-08-21	インスリン誘導体
US4604376A (en)	1986-08-05	Enteric compounds and complexes
RU2198181C2 (ru)	2003-02-10	Не содержащие цинк кристаллы инсулина для применения в легочных композициях
CN1159950A (zh)	1997-09-24	控制活性成分释放的生物粘合药物组合物
JPH02101022A (ja)	1990-04-12	糖尿病治療用医薬組成物
JPH05508616A (ja)	1993-12-02	治療用エアロゾル剤
JPH026405A (ja)	1990-01-10	経肺薬物送達用組成物
JP2720899B2 (ja)	1998-03-04	経粘膜吸収促進剤及びこれを用いた経鼻投与剤
JPH04149126A (ja)	1992-05-22	経粘膜投与用医薬組成物
JPS6039647B2 (ja)	1985-09-06	ガンマ−ｌ−グルタミル−タウリンの単離方法
JPH0585942A (ja)	1993-04-06	インターフエロン−ヒアルロン酸及び／又はその塩の結合体
JP2001505222A (ja)	2001-04-17	生物体にペプチド系医薬を導入するための局所用製剤
JP3655645B2 (ja)	2005-06-02	経粘膜投与剤
US4820811A (en)	1989-04-11	Amine reacted therapeutic agents
JPH0242027A (ja)	1990-02-13	経粘膜吸収促進剤及びこれを用いた経鼻投与剤
JPH02214A (ja)	1990-01-05	鼻腔内投与用製剤
JPH01233230A (ja)	1989-09-19	経粘膜吸収促進剤及びこれを用いた点鼻剤
CA2288968A1 (en)	1998-10-22	Permucous preparation
JPH02306919A (ja)	1990-12-20	鼻粘膜血管透過性抑制剤
WO1994012186A1 (en)	1994-06-09	Prostaglandin derivative having radioprotective effects
JPWO1998046269A1 (ja)	2000-10-03	経粘膜投与製剤
MXPA99008401A (en)	2000-09-04	Zinc free insulin crystals for use in pulmonary compositions

JPH01500116A - インシユリン製剤 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=8108089

Family Applications (1)

Country Status (13)

Cited By (1)

Families Citing this family (48)

Citations (3)

Family Cites Families (13)

Patent Citations (3)

Cited By (1)

Also Published As

Similar Documents